Candidate for worst name: FDVRF Facedrive Inc. 11.23 -0.66(-5.55%) This is a ride share stk in Canada with...all of 30 employees! Company Profile Facedrive Inc. operates as a ride-sharing company in Canada. It offers Facedrive, a ridesharing platform; and TraceSCAN, a COVID-19 contact tracing app. The company was incorporated in 2016 and is headquartered in Richmond Hill, Canada. The interesting part is they are carbon neutral so this may be The First Electric Ride share program which got me thinking of the other big boys.. Facedrive is a Toronto-based ridesharing company that operates in the technology sector. It was created to offer a transportation network that was first and foremost socially responsible and CO2 emissions neutral.
Score Media, Penn and Bally's among those seen benefiting from Canadian sports betting developments Nov. 27, 2020 12:38 PM ETScore Media and Gaming Inc. (TSCRF) Ontario-based Score Media and Gaming(OTCPK:TSCRF)is called by Union Gaming one of the big winners from Canada moving toward allowing single event sports betting. Investors are seizing on that upside potential, with shares of Score up more than 20% in Toronto trading on high volume. Analyst John DeCree says another likely beneficiary is Penn National Gaming (PENN+1.9%), which received a 4.7% equity stake in Score as part of its market access agreement with the company in the U.S. He notes that Bet.Works, which is being acquired by Bally's (BALY-2.6%), is a logical partner for Score in Canada. International Game Technology (IGT+4.2%) and Scientific Games (SGMS+1.1%) are expected to have a good opportunity to participate in Canada as well. On the B2B side, Kambi Group(OTCPK:KMBIF)and DraftKings'(NASDAQ:DKNG) SBTech are said to also be in the mix. Single event sports betting could also move the needle for casino operators Century Casinos (CNTY-0.2%) and Caesars Entertainment (CZR+0.3%), per DeCree.
Supercuts owner Regis stock a post-COVID play, Barron's says 10:10 RGS One company that is poised to meet pent-up demand next year and beyond is Regis, an owner and franchiser of about 6,700 barbershops and salons in the U.S., the U.K., and Canada, Nicholas Jasinski writes in this week's edition of Barron's. There is no other publicly traded company in this highly fragmented market, and many small, independent salons and barbershops won't be able to survive the pandemic, the author notes, adding that Regis stands a good chance of being able to grow its market share, currently less than 10% in North America.
The week was led by Russian e-commerce platform Ozon Holdings (NASDAQ:OZON), which upsized and priced above range to raise $990 million at a $5.4 billion market cap. Backed by private equity firm Baring Vostok and Russian conglomerate Sistema, Ozon maintains a growing share of the underpenetrated Russian e-commerce market. While unprofitable, the company boasts positive contribution margins and strong GMV growth. Ozon finished up 30%. Canadian powerboat manufacturer Vision Marine Technologies (VMAR) upsized and priced at the high end to raise $24 million at a $79 million market cap. The company currently offers four models of electric powerboats, producing 46 in the last fiscal year. It is has yet to commercialize its electric powertrains, though it has letters of intent for 186 units. Vision Marine finished up 42%.
Well we missed out bad on this Amazon of Africa Jumia... and I've been looking for other Amazon's of other places.. Sweden? Here is the Amazon of Russia... I dunno... Can we trust these guys?
Regis ($RGS) is a good find. I forgot about it. Its been around awhile. I wish you'd have thought about it last month though, we missed the big move, 50% since 11/1. Ya know one thing I like about it as crazy as this sounds... its based in Minneapolis, MN. That place... I don't know what it is... maybe the cold, maybe the Scandinavian work ethic... what are those people Lutherans? Presbyterians? They're one of those. Either way, those iceheads know how to run a tight ship. Every company I have ever looked into that was based out of that place, has done well over the years. Target, Best Buy, United Healthcare, 3M, Cargill, Ameriprise. I mean its like ground zero of safe steady eddie stocks. The Mayo Clinic is there too, that's pretty well respected worldwide. Must be the cold. I mean who's gonna skip work for a day in the park with the family when its -30 Fahrenheit out. And in the summer... I think mosquitos are the state bird. Nasty place imo. Lots of tall blonds there however; probably distant cousins of those Russian track videos you like so much. Anyway, yeah Regis has $11 in it easy before earnings in February. Its not a Corsair or a GrowGen... we're not quadruple our money in 5 days, but 30% in a few months is 30%. Any pull-back to the low $7's should be bought aggressively imo.
Inside Curaleaf Billionaire Boris Jordan’s Hunger To Become The ‘Frito-Lay’ Of Cannabis ARSENY NESKHODYMOV FOR FORBES The largest marijuana company in America is on a mission to convert non-consumers into customers by selling them highly formulated products. On the rolling hills of Long Island’s North Shore Country Club, overlooking Hempstead Harbor, a 54-year-old billionaire is getting high with his friends. Boris Jordan, a New York native who made his fortune in Moscow in the 1990s and built Curaleaf into the largest cannabis company in America, is encouraging his guests to try his newest product—a fast-acting nano-emulsion tincture made with tetrahydrocannabinol (THC). None of the guys have smoked weed since college, and neither has Jordan, but he drops 5 milligrams of THC into everyone’s water and within 10 minutes they’re feeling like a billion bucks. “I never have been so excited for a product in my life. I felt fantastic,” says Jordan, who actually prefers a slow-release THC capsule to help him sleep. “It just relaxes you and my golf game was much better. I really suck at golf, so trust me, I needed it.” Jordan, who is worth $1.6 billion and owns about 30% of Curaleaf, believes the new cannabis tincture, and a gummy made with the same fast-acting bioavailability, will be a “home run.” But, he’s much more excited about how the new adult-use markets in New Jersey and Arizona will be a windfall for his company. On Election Day, voters in those two states passed legalized recreational sales. (Voters in South Dakota also passed medical and adult-use, while Utah and Mississippi passed medical marijuana laws.) The new adult-use markets, according to a note from Cowen, will unlock a black market worth a combined $3 billion-plus. Curaleaf, with its 96 dispensaries and 23 cultivation sites across as many states, is the only operator with dominant positions in both New Jersey and Arizona, where it is the number-one and number-two market leader in medical marijuana, respectively. “The impact to the Curaleaf growth rate will be dramatic,” says Jordan via Zoom, sitting in his living room at his home in Sea Cliff, Long Island. “New Jersey is a watershed event—what will happen is that Pennsylvania, New York and Connecticut will now go adult use.” The company also has a dominant position in New York’s limited medical market, as well as a strong presence in Pennsylvania and Connecticut. If Jersey proves to be a tipping point for adult-use on the East Coast and New York legalizes recreational cannabis in 2021—as Governor Andrew Cuomo has assured residents will happen—and Pennsylvania and Connecticut follow, Jordan says “it’s blue skies” for Curaleaf. Jordan’s company is perhaps the biggest winner in the industry after Election Day. Vivien Azer, an analyst at Cowen who covers beverages, tobacco, and cannabis, has given Curaleaf—which recently reported a record $182.4 million in third quarter revenue, up 195% year over year—an “outperform” rating. Liquid Gold: Curaleaf acquired THC concentrate maker Select last year. The vape and edible brand has become the heart of its recreational cannabis product line. curaleaf “I think they’re incredibly well positioned. Their scale is unparalleled,” says Azer. With New Jersey transitioning to an adult-use market, Azer says the state will go from under $250 million in annual sales to at least $1.8 billion by 2025. Curaleaf currently has an estimated 40% market share in the state. “They are building an incredibly durable business model by establishing market share leadership across a number of geographies.” In Arizona, Curaleaf is the second-largest player with 8 dispensaries and two cultivation facilities, mostly in Phoenix, and the company will open two more dispensaries in 2021. In New Jersey, the company will open its second dispensary next year and by March it will complete a new 100,000-square-foot indoor cultivation site, tripling its grow capacity and cementing its position as the state’s largest cultivator and wholesaler. (The company will also open an outdoor grow and a third dispensary sometime in 2021.) “In New Jersey, our goal is different,” Jordan continues. “We’re looking to be the wholesaler—that’s why we’re building the big grow, so we can supply the whole market with product.” “We’re making the products much more mainstream for our customer base—we’ll be no different than Coca-Cola or Frito-Lay.” Boris Jordan, chairman of Curaleaf Curaleaf is not in the craft, sun-grown, hand-trimmed, high-end flower business targeting legacy cannabis consumers. Rather, the company is focused on the highly formulated products sector, targeting people who partook in college and want to get back into it, senior consumers looking for something to ail their pain, and Millennial newbies. “I look at Curaleaf as a consumer-packaged goods company,” says Jordan, who assumed control of Curaleaf in 2013 through his private equity company and took it public on the Canadian Stock Exchange in 2018. “We’re making the products much more mainstream for our customer base—we’ll be no different than Coca-Cola or Frito-Lay.” For now, Jordan’s company has two main brands—Curaleaf, a wellness brand that sells cannabis flower and makes THC and CBD capsules, lotions, and tinctures. And Select, a lifestyle brand that sells THC vape pens and gummies and CBD tinctures. Jordan says that while the company is doubling its cultivation capacity next year, it plans to get out of cultivation completely. When he took over Curaleaf in 2013, 90% of the product sold was flower and 10% of sales were edibles and other products. Today, he says Curaleaf’s sales are 55% “everything else” and 45% flower. He predicts flower to drop further as vapes, edibles, pills, gummies, tinctures make up 75% of the company’s sales. “Now, in the everything else is where we see a tremendous market opportunity,” says Jordan. “We want to be a highly formulated product company. Not the customer who is looking to roll a joint, but someone who is looking to replace excessive alcohol, someone who is looking for a highly formulated, very safe, very tasty product.” This strategy of ditching cultivation and focusing on processing and manufacturing products is akin to other vice industries such as cigarettes. Cowen’s Azer believes this is the best strategy for the long term. “In my experience, covering traditional multi-billion GPG companies like Altria, yeah, they manufacture Marlboro cigarettes,” she says, “but they don’t grow the tobacco.” House of Flowers: Curaleaf will double its cultivation capacity across the U.S in 2021, but Jordan says the company will eventually stop growing cannabis and focus on product formulation. curaleaf To reinforce this packaged goods strategy, Jordan has also brought in new leadership. In January 2021, Curaleaf’s longtime CEO, Joe Lusardi will step down and become vice chair to make room for Joe Bayern, the current president, who previously worked for Dr. Pepper Snapple, and Cadbury. During a recent earnings call, Bayern said his goal is to bring customers who have never consumed cannabis, or are lapsed consumers, to the legal market. Currently, only 5% to 7% of American households consume cannabis products, he said, but that number is expected to grow and help the industry become a $100 billion market in 10 years. “Curaleaf is uniquely positioned to lead this growth and address the roughly 93% to 95% of consumers yet to experience cannabis,” Bayern noted. “That's an amazing opportunity.” Curaleaf’s growth hit hyperdrive in the last year. In September 2019, the company had 49 dispensaries, but now has 96. Its growth is thanks to Jordan’s rollup strategy, one he said he refined in Europe by consolidating the data center industry with Telecity. In 2019, Curaleaf announced two of its largest acquisitions that transformed the company—Cura Partners (owner of Select), a vape and THC concentrates company, which Curaleaf bought in an all stock deal valued at $365 million, and Grassroots, one of the largest private cultivators and retailers with 30 dispensaries across Illinois, Nevada, Michigan, Oklahoma, Ohio, North Dakota, which Curaleaf bought for $830 million. The company’s aggressive acquisitiveness has also cost a lot—Curaleaf has $300 million in debt—but it has posted solid quarter-to-quarter revenue growth since going public in 2018. Bright Idea: Jordan believes the cannabis green rush benefits from colorful packaging and slick design, like any other consumer packaged good. curaleaf Curaleaf, of course, has a host of formidable competitors—most notably Green Thumb Industries and Cresco. But the legal industry is still relatively small. Jordan says he doesn’t consider the legal market operators his competitors. By the end of 2020, legal cannabis sales are only expected to reach $20 billion while the illegal market is estimated at more than $100 billion. Legal cannabis companies are subject to an effective tax rate of nearly 50%, as well as expensive testing requirements and onerous banking terms. Jordan expects Congress to pass cannabis banking regulations this year, which will help but the industry needs to be legalized at the federal level. “Let’s be honest,” Jordan says. “Our competition is not each other—our competition is the drug dealer, that’s who we’re competing against.” His mission is to make that illicit market go up in smoke.